Melatonin pathway proteins

Melatonin pathway proteins encompass all proteins that participate in melatonin signaling and action, the most notable of which are the melatonin receptors MT1 and MT2 (encoded by MTNR1A and MTNR1B)[1][4]. These GPCRs mediate the regulatory effects of melatonin on circadian rhythms, sleep-wake cycles, antioxidant defenses, immune responses, and cell proliferation. Other proteins proposed to bind or interact with melatonin include enzymes such as quinone reductase 2 (occasionally referred to as the MT3 binding site) and carrier proteins like serum albumin, which facilitate melatonin transport but are not direct therapeutic targets. Melatonin’s biological activities make it a candidate for treating a diverse range of diseases, including sleep disorders, neurodegenerative diseases, cancer, inflammation, and metabolic/cardiovascular conditions[1][2][3][4][5][6]. Drugs targeting MT1/MT2, such as ramelteon and agomelatine, provide therapeutic benefits mainly for sleep disorders and circadian rhythm disturbances, but ongoing research explores their potential in broader disease settings.\n\nFor precise drug targeting and structured annotation, use \"Melatonin receptor type 1A (MT1)\" or \"Melatonin receptor type 1B (MT2)\" as canonical targets rather than \"Melatonin pathway proteins,\" which is not sufficiently specific or scientifically accurate[1][4].

Other names

MTNR1A (for MT1)MTNR1B (for MT2)Melatonin GPCRsMelatonin binding sitesMelatonin receptor subtypes MT1/MT2Melatonin target proteins

Agonism of melatonin receptors (MT1/MT2) to modulate sleep and circadian pathways\nInhibition of cAMP and modulation of MAPK/ERK signaling\nModulation of gene expression related to apoptosis, oxidative stress, and immune signaling\nAntioxidant activity and mitochondrial protection